Literature DB >> 11422754

Microalbuminuria in type 1 diabetes: rates, risk factors and glycemic threshold.

N Chaturvedi1, S Bandinelli, R Mangili, G Penno, R E Rottiers, J H Fuller.   

Abstract

BACKGROUND: The occurrence of microalbuminuria in type 1 diabetes is strongly predictive of renal and cardiovascular disease and is still likely to occur despite improvements in glycemic control. A better understanding of microalbuminuria is required to inform new interventions. We determined the incidence and risk factors for microalbuminuria [albumin excretion rate (AER) 20 to 200 microg/min] in the EURODIAB Prospective Complications Study.
METHODS: This is a seven-year follow-up (between 1988 and 1991) of 1134 normoalbuminuric men and women (aged 15 to 60) with type 1 diabetes from 31 European centers. Risk factors and AER were measured centrally.
RESULTS: The incidence of microalbuminuria was 12.6% over 7.3 years. Independent baseline risk factors were HbA1c (7.1 vs. 6.2%, P = 0.0001) and AER (9.6 vs. 7.8 microg/min, P = 0.0001) and, independent of these, fasting triglyceride (0.99 vs. 0.88 mmol/L, P = 0.01), low-density lipoprotein cholesterol (3.5 vs. 3.2 mmol/L, P = 0.02), body mass index (24.0 vs. 23.4 kg/m2, P = 0.01), and waist to hip ratio (WHR; 0.85 vs. 0.83, P = 0.009). Triglyceride and WHR risk factors were nearly as strong as AER in predicting microalbuminuria (standardized regression effects of 1.3 for triglyceride and WHR and 1.5 for AER). Blood pressure at follow-up, but not at baseline, was also raised in those who progressed. There was no evidence of a threshold of HbA1c on microalbuminuria risk.
CONCLUSIONS: The incidence of microalbuminuria in patients with type 1 diabetes remains high, and there is no apparent glycemic threshold for it. Markers of insulin resistance, such as triglyceride and WHR, are strong risk factors. Systemic blood pressure is not raised prior to the onset of microalbuminuria.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11422754     DOI: 10.1046/j.1523-1755.2001.00789.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  41 in total

1.  Event and Cost Offsets of Switching 20% of the Type 1 Diabetes Population in Germany From Multiple Daily Injections to Continuous Subcutaneous Insulin Infusion: A 4-Year Simulation Model.

Authors:  York Francis Zöllner; Ralph Ziegler; Magnus Stüve; Julia Krumreich; Marion Schauf
Journal:  J Diabetes Sci Technol       Date:  2016-08-22

2.  Association of diet and lifestyle with glycated haemoglobin in type 1 diabetes participants in the EURODIAB prospective complications study.

Authors:  S N Balk; D A J M Schoenaker; G D Mishra; M Toeller; N Chaturvedi; J H Fuller; S S Soedamah-Muthu
Journal:  Eur J Clin Nutr       Date:  2015-07-15       Impact factor: 4.016

3.  Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005.

Authors:  P Rossing
Journal:  Diabetologia       Date:  2005-12-09       Impact factor: 10.122

4.  Predicting major outcomes in type 1 diabetes: a model development and validation study.

Authors:  Sabita S Soedamah-Muthu; Yvonne Vergouwe; Tina Costacou; Rachel G Miller; Janice Zgibor; Nish Chaturvedi; Janet K Snell-Bergeon; David M Maahs; Marian Rewers; Carol Forsblom; Valma Harjutsalo; Per-Henrik Groop; John H Fuller; Karel G M Moons; Trevor J Orchard
Journal:  Diabetologia       Date:  2014-09-04       Impact factor: 10.122

5.  Post-transplant diabetes mellitus associated with heart and lung transplant.

Authors:  Oratile Kgosidialwa; Kieran Blake; Oisin O'Connell; Jim Egan; Jim O'Neill; Mensud Hatunic
Journal:  Ir J Med Sci       Date:  2019-07-27       Impact factor: 1.568

6.  Do European people with type 1 diabetes consume a high atherogenic diet? 7-year follow-up of the EURODIAB Prospective Complications Study.

Authors:  Sabita S Soedamah-Muthu; Nish Chaturvedi; John H Fuller; Monika Toeller
Journal:  Eur J Nutr       Date:  2012-12-07       Impact factor: 5.614

7.  Progression to microalbuminuria in type 1 diabetes: development and validation of a prediction rule.

Authors:  Y Vergouwe; S S Soedamah-Muthu; J Zgibor; N Chaturvedi; C Forsblom; J K Snell-Bergeon; D M Maahs; P-H Groop; M Rewers; T J Orchard; J H Fuller; K G M Moons
Journal:  Diabetologia       Date:  2009-11-04       Impact factor: 10.122

8.  Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB Prospective Complications Study.

Authors:  J W M Nin; I Ferreira; C G Schalkwijk; M H Prins; N Chaturvedi; J H Fuller; C D A Stehouwer
Journal:  Diabetologia       Date:  2009-01-30       Impact factor: 10.122

9.  Alterations in retinal microvascular geometry in young type 1 diabetes.

Authors:  Muhammad Bayu Sasongko; Jie Jin Wang; Kim C Donaghue; Ning Cheung; Paul Benitez-Aguirre; Alicia Jenkins; Wynne Hsu; Mong-Li Lee; Tien Y Wong
Journal:  Diabetes Care       Date:  2010-03-18       Impact factor: 19.112

10.  Relationship between plasma sialic acid and fibrinogen concentration and incident micro- and macrovascular complications in type 1 diabetes. The EURODIAB Prospective Complications Study (PCS).

Authors:  S S Soedamah-Muthu; N Chaturvedi; J C Pickup; J H Fuller
Journal:  Diabetologia       Date:  2008-01-09       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.